Journal of Health Care Communications Open Access

  • ISSN: 2472-1654
  • Journal h-index: 15
  • Journal CiteScore: 6.77
  • Journal Impact Factor: 7.34
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Commentary - (2022) Volume 7, Issue 5

Medical Management and Advanced Therapies for Heart Failure in Seniors Citizens
Yukari Seko*
Department of Cardiology, Western University, Canada
*Correspondence: Yukari Seko, Department of Cardiology, Western University, Canada, Email:

Received: 02-May-2022, Manuscript No. IPJHCC-22- 13625; Editor assigned: 04-May-2022, Pre QC No. IPJHCC-22- 13625(PQ); Reviewed: 18-May-2022, QC No. IPJHCC-22- 13625; Revised: 24-May-2022, Manuscript No. IPJHCC-22- 13625(R); Published: 30-May-2022, DOI: 10.35248/2472-1654-7.5.70020


As the population ages and the prevalence of cardiovascular breakdown increases, cardiologists and geriatricians can expect to see more older patients with cardiovascular breakdown in their daily practise. As clinical consideration and innovation have progressed, the board’s options for cardiovascular breakdown have grown. However, current rules rely on studies of younger populations, and evidence in older populations is lacking. The executives believe that pharmacologic treatment, which has been shown to reduce long-term mortality, will continue to be the foundation of cardiovascular breakdown. Implantable devices are being used more frequently in more advanced patients to prevent unexpected cardiovascular death.

Although high-level treatments have given patients with endstage cardiovascular breakdown more options, their use in more advanced patients is still limited. In this audit, we look at the current clinical management guidelines for cardiovascular breakdown in older people, as well as the growing body of knowledge about cutting-edge treatments like heart transplantation in older people with end-stage cardiovascular breakdown.

The typical future upon entering the world has expanded and is expected to rise as medicine, innovation, and protection care advance. There has been an increase in the population 65 years and older, as well as the elderly population over 85 years old, all over the world. By 2050, it is estimated that 17% of the total population and 21% of the population of the United States (US) will be over 65 years old. By 2060, the average lifespan in the United States is expected to be 85.6 years. Cardiologists and geriatricians can expect an increase in the number of older patients with multimorbidity and cardiovascular disease as the population ages.

The prevalence of cardiovascular breakdown rises with age and is estimated to affect more than 6 million adults in the United States. Pervasiveness nearly copies from roughly 6% of the population between the ages of 60 and 79 to 11% of those over the age of 80. The increased prevalence in the older population is likely due to advancements in years-related cardiovascular breakdown risk factors such as hypertension, coronary artery disease, diabetes, and underlying and utilitarian changes.

The number of more advanced cardiovascular breakdown patients is expected to rise as the population ages and clinical treatment improves. Despite the fact that clinical treatment has improved cardiovascular breakdown, mortality and hospitalisation remain high. More seasoned patients were generally underrepresented or avoided from the milestone preliminaries that prompted the momentum cardiovascular breakdown rules, however we keep on applying the ebb and flow suggestions to our more seasoned patients.

Heart transplantation remains the best restorative option for end-stage cardiovascular failure, but age continues to be a barrier to relocation at many foundations. Mechanical advancements, on the other hand, have allowed more patients with end-stage cardiovascular breakdown to receive an LVAD, but more experienced patients are more prone to complications. More recent LVAD innovation may alleviate those issues, but the number of more experienced LVAD patients has not increased in recent years. Adopting a multifactorial strategy to mind, while thinking about geriatric disorders, polypharmacy, and expected endurance while endorsing and offering progressed treatments, means a lot to our more established patients with cardiovascular breakdown.



Conflict of Interest

The author declares there is no conflict of interest in publishing this article has been read and approved by all named authors.

Citation: Seko Y (2022) Medical Management and Advanced Therapies for Heart Failure in Seniors Citizens . J Healthc Commun. 7:70020.

Copyright: © Seko Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.